

**We can accomplish more together than each organization can achieve working alone**



Worldwide Innovative Networking  
in personalized cancer medicine


## WIN's journey

Over 10 years ago, WIN was founded by Dr. John Mendelsohn and Prof. Thomas Tursz, who understood that union makes the force to fight cancer.

A special issue of Nature Reviews in Clinical Oncology delivered a "birth certificate" at the very early inception of WIN.



Left: John Mendelsohn, Chairman Emeritus  
Right: Thomas Tursz, past Vice Chairman



Left: Richard L. Schilsky, Chairman;  
Right: Josep Taberero, Vice-Chairman and Chairman SAB

Dr. Richard L. Schilsky enthusiastically adhered to the program, as chairman of the Scientific Advisory Board (SAB).

He was then appointed Chairman of WIN and is supported by Josep Taberero as vice-chairman and chairman of the SAB.

10 years later, with member contributions, trust, and hard work, the WIN organization is structured, active with a consolidated team and motivated cancer centers around the world. More importantly, WIN demonstrated its capability to conduct and deliver complex and innovative international trials using transcriptomics (WINTHER trial, Phase I SPRING trial) and our capability to publish our ground-breaking research in prestigious journals.

## WINTHER

The publication of **WINTHER trial** results was ranked 13<sup>th</sup> in all Nature Medicine articles (J. Rodon et al Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial). Nature Medicine 2019, <https://doi.org/10.1038/s41591-019-0424-4>


WINTHER was also selected as the success story of the European Union Framework Program 7 (EU FP7).

## NEWSLETTER: MAY 2021

### New Appointments



Congratulations to Dr. Razelle Kurzrock for becoming Chief Medical Officer, WIN in addition to her role as Chair, Clinical Trials Committee, WIN



Congratulations to Shai Magidi for becoming IT Data Manager, WIN

## Members' news

### FUSCC celebrates 90<sup>th</sup> Anniversary



We would like to extend our warm congratulations to Shanghai Medical College of Fudan University for achieving their auspicious occasion of 90 years anniversary. We are grateful to Fudan University Shanghai Cancer Center as one of the founding and active members of the WIN Consortium in personalized cancer medicine.

## New WIN Members

We are delighted to welcome back WIN's founding member [Gustave Roussy](#), Villejuif, France.

General Assembly representatives:



Left: Michel Ducreux, MD, PhD, Head of Digestive Oncology Department; Right: Fabrice André, MD, PhD, Head of Research and Professor in the Department of Medical Oncology, Gustave Roussy, Paris, France.

We would like to extend a warm welcome to our new member Catalan Institute of Oncology (ICO), Spain.



General Assembly representatives:



Left: Ramón Salazar, MD PhD, Head of Medical Oncology Department, Right: Juan Martín Liberal, MD PhD, Consultant Medical Oncologist, Catalan Institute of Oncology, Barcelona, Spain.

WINTHER (NCT01856296) is the first trial that used transcriptomics in a prospective clinical setting. To this effect, the dual tumor and analogous normal matched tissue biopsies were introduced. To date, the trial offers unprecedented high-quality data for all patients enrolled with genomics, transcriptomics from dual fresh frozen tissue biopsies and clinical outcomes. The Clinical Management Committees chaired by Dr. Razelle Kurzrock with participation of all site investigators and support teams based on a dedicated user-friendly website remains one of the fundamental assets of the trial.

This international investigator-initiated trial activated in 5 countries and 7 sites was approved by the WIN SAB and funded through grants from EU FP7, Foundation ARC for cancer research, France and Pfizer, and was supported by participating members of the WIN Consortium, to whom we express our gratitude.

### SPRING

The Phase I of the IND131601 SPRING trial (NCT03386929) is completed. The triple therapy avelumab (anti-PD-L1), palbociclib (anti CDK4/6 and axitinib (anti-VEGFR) was well tolerated at dose level 1, which is the RP2D. 15 patients were treated and 14 were fully evaluable. 4 patients (27%) achieved PR (PFS 14, 24, 25 and 144+ weeks) incl. 2 of the responders had failed a prior checkpoint inhibitor. 4 patients were SD  $\geq$ 24 weeks. Overall 8 out of 15 patients (53%) achieved clinical benefit.

This international investigator-initiated trial activated in 4 countries and 5 sites was funded by Foundation ARC for cancer research, France and WIN. The study drugs were provided by Pfizer, as part of an alliance between Merck KGaA, Darmstadt, Germany and Pfizer.

The manuscript will be submitted as brief clinical report to Clinical Cancer Research.

## Digital Display Precision Predictor (DDPP)

Using the WINTHER database, WIN was able to create the Digital Display Precision Predictor (DDPP) biomarker strategy and tool enabling to to predict the duration of response of patients under targeted and immuno therapies.

Lazar, V., et al., Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival. **npj Precision Oncology** (2021 5:33) (<https://doi.org/10.1038/s41698-021-00171-6> ) was ranked one of the top 1<sup>st</sup> articles in Nature Research NPJ Precision Oncology.

The story behind the paper was also published in [Nature Community](https://go.nature.com/3aAHnm). <https://go.nature.com/3aAHnm>  
[Genomeweb](https://go.nature.com/3aAHnm) covered this article.

We dedicated this paper, in memory of Dr. John Mendelsohn, Prof. Thomas Tursz and [Gaspard Bresson](#), Catherine Bresson's son who passed away with cancer at the tender age of 10, subsequently, it led Catherine to join WIN and become the heart of the Operational Team at the WIN Consortium.

Two other manuscripts are in preparation and new developments are ongoing.



Left: Gaspard Bresson,  
Right: Catherine Bresson,  
WIN Director Operational Team

We would like to thank our members for their great support and active participation to make the WIN dream happen.

We will continue to deploy all our energy to honor the memory of Dr. John Mendelsohn and Prof. Thomas Tursz to improve the lives of cancer patients worldwide.

### WIN Consortium Members

**Academic Institutions in Americas**

**Academic Institutions in Asia**

**Academic Institutions in Europe**

### Industries

**Non-Profit Organisations**

### WIN Consortium WIN Symposium

Follow us on:

- [Twitter](#)
- [Facebook](#)
- [LinkedIn](#)